alexion pharmaceuticals , inc .
notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) in 2006 , we completed a final phase iii trial of pexelizumab .
after reviewing results from that trial , we along with p&g , determined not to pursue further development of pexelizumab .
effective march 30 , 2007 , we and p&g mutually agreed to terminate the collaboration agreement .
as the relevant agreement has been terminated in march 2007 , the remaining portion of the $ 10000 non-refundable up-front license fee , or $ 5343 , was recognized as revenue in the year ended december 31 , 2007 and is included in contract research revenues .
license and research and development agreements we have entered into a number of license , research and development and manufacturing development agreements since our inception .
these agreements have been made with various research institutions , universities , contractors , collaborators , and government agencies in order to advance and obtain technologies and services related to our business .
license agreements generally provide for an initial fee followed by annual minimum royalty payments .
additionally , certain agreements call for future payments upon the attainment of agreed upon milestones , such as , but not limited to , investigational new drug , or ind , application or approval of biologics license application .
these agreements require minimum royalty payments based on sales of products developed from the applicable technologies , if any .
clinical and manufacturing development agreements generally provide for us to fund manufacturing development and on-going clinical trials .
clinical trial and development agreements include contract services and outside contractor services including contracted clinical site services related to patient enrolment for our clinical trials .
manufacturing development agreements include clinical manufacturing and manufacturing development and scale-up .
we have executed a large-scale product supply agreement with lonza sales ag for the long-term commercial manufacture of soliris ( see note 9 ) .
in order to maintain our rights under these agreements , we may be required to provide a minimum level of funding or support .
we may elect to terminate these arrangements .
accordingly , we recognize the expense and related obligation related to these arrangements over the period of performance .
the minimum fixed payments ( assuming non-termination of the above agreements ) as of december 31 , 2007 , for each of the next five years are as follows : years ending december 31 , license agreements clinical and manufacturing development agreements .

years ending december 31,
license agreements
clinical and manufacturing development agreements
2008
$ 707
$ 2860
2009
552
3750
2010
322
7500
2011
300
7500
2012
300
7500

.

Question: what is the percent change in minimum fixed payments of clinical and manufacturing development agreements between 2008 and 2009?
Answer: 31.1%

Question: what is the percent change in minimum fixed payments of license agreements between 2008 and 2009?
Answer: -21.9%